Last $15.05 USD
Change Today -0.01 / -0.07%
Volume 229.5K
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:05 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Stephen K. Doberstein Ph.D.

Chief Scientific Officer and Senior Vice President, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

55$1,159,605
As of Fiscal Year 2013

Background*

Dr. Stephen K. Doberstein, Ph.D, Steve has been Chief Scientific Officer and Senior Vice President of Nektar Therapeutics since January 6, 2010. Dr. Doberstein served as Vice President of Research of XOMA Ltd. since October 28, 2008. He has 17 years of experience in biotechnology research and development. Most recently, he served as Vice President of Research at Five Prime Therapeutics, Inc., since July 2004. Prior to his position at Five Prime, he served as Vice President ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

BS
University of Delaware
PhD
Johns Hopkins School of Medicine

Other Affiliations*

Annual Compensation*

Salary$459,722
Total Annual Compensation$459,722

Stock Options*

All Other Compensation$9,513
Exercisable Options637,914
Exercisable Options Value$1,233,241
Unexercisable Options162,086
Unexercisable Options Value$458,159
Total Value of Options$1,691,400
Total Number of Options800,000

Total Compensation*

Total Annual Cash Compensation$700,235
Total Short Term Compensation$459,722
Other Long Term Compensation$9,513
Total Calculated Compensation$1,159,605
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $15.05 USD -0.01

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$515.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director and Member of Strategic Operations Committee
Emergent BioSolutions, Inc.
$1.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.